ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1533	National Cancer Institute	Html	en	Cancell/Cantron/Protocel (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of Cancell/Cantron/Protocel as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	peer-reviewed scientific journals 0.623029 NCI Tumor Cell 0.661367 cell lines 0.687144 human cells 0.635256 aerobic metabolism 0.794285 bacterium P. cryptocides. 0.62979 PDQ cancer information 0.88904 cancer development. 0.663979 vitro NCI-60 DTP 0.62954 somewhat different explanations 0.628856 Cancer Terms 0.627276 principal manufacturers 0.71541 certain damaging conditions 0.634012 Topical skin application 0.63342 substantial antitumor activity. 0.625666 cancer information summary 0.875855 breast cancer prevention 0.656117 Tumor Cell Line 0.74552 clinical drug research 0.64982 Cancell/Cantron/Protocel 0.841588 Investigational New Drug 0.649141 cancerous cells 0.717346 NCI’s PDQ 0.624803 NCI PDQ cancer 0.71862	residual aerobic metabolism 0.655098 NCI Dictionary 0.62162 unapproved new drug 0.650693 numerous animal experiments 0.621001 completely primitive state 0.63055 Therapies Editorial Board 0.638692 vivo situation 0.631095 excretion—an unlikely situation 0.620899 original manufacturer 0.721066 cancer cells 0.761265 damaged normal cells 0.711253 critical point 0.644689 reference citations 0.63628 idealized conditions Cancell/Cantron/Protocel 0.671023 adult-onset diabetes mellitus 0.639765 additional biochemical reactions 0.628258 cell line screen 0.841075 National Cancer Institute 0.793891 NCI human cancer 0.696144 normal cells 0.997775 chronic energy stress 0.639389 Human Tumor Cell 0.638074 cancer information summaries 0.702185 artificial media 0.635059	CLICK HERE
1586	National Cancer Institute	Html	en	Vaginal Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of vaginal cancer.	cell vaginal cancer 0.360195 lymph node dissection 0.326781 body 0.312996 abnormal areas 0.281727 PDQ cancer information 0.334259 vaginal cancer 0.760063 clinical trial search 0.36299 clinical trials 0.668187 cancer information summary 0.310305 clinical trial 0.454575 squamous cell cancer 0.354582 Vaginal Cancer Treatment 0.308045 Pap test 0.272131 patients 0.293377 IVB vaginal cancer 0.318217 NCI PDQ cancer 0.278314 malignant tumor cells 0.275963 Treatment Option Overview 0.274359 lymph nodes 0.290946 radiation therapy 0.589716 General information 0.282628 general cancer information 0.271401 treatment 0.460915 abnormal cells 0.349727 wide local excision 0.321438	Recurrent vaginal cancer 0.337303 new cancer treatments 0.27048 NCI-supported cancer 0.305828 cancer cells 0.3346 vaginal intraepithelial neoplasia 0.296856 Cancer Information Service 0.272009 vaginal cancer spreads 0.334927 squamous cell 0.369952 stage ivb 0.271421 treatment clinical trials 0.293735 National Cancer Institute 0.348129 tumor cells 0.290691 new treatment 0.303739 cervix 0.280807 IVA vaginal cancer 0.291708 external radiation therapy 0.454541 cancer clinical trials 0.3729 cells 0.353506 stage 0.310322 cancer information summaries 0.270039 comprehensive cancer information 0.270279 internal radiation therapy 0.457186 Cervical Cancer Treatment 0.289689 cancer 0.911572	CLICK HERE
1770	National Cancer Institute	Html	es	Prurito (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del prurito (picazón en la piel) como complicación del cáncer o su tratamiento. Se consideran los abordajes de manejo y tratamiento del prurito.	haemodialysis patients 0.476654 Section XII 0.477073 Rubenstein E 0.559292 Sin embargo 0.803552 Scientific American Medicine 0.676981 categoría farmacológica medicamento 0.526417 Am Acad Dermatol 0.571569 Clin Res 0.479277 Wolff K 0.536775 Acad Dermatol Venereol 0.493209 Farber EM 0.55456 patients with atopic 0.550773 Cancer Nursing 0.471101 PDQ Prurito 0.665745 Dermatol Venereol Leprol 0.6251 with atopic dermatitis 0.566467 toxina botulínica 0.473345 reacciones cutáneas 0.538217 patients with 0.621762 chronic idiopathic 0.533598 Pain Symptom Manage 0.649291 neuropathic pruritus 0.513717 Scientific American 0.875762 Oncol Nurs Forum 0.782558 Malignant cutaneous tumors 0.546882	Dosis Comentarios Referencias 0.53479 General Medicine 0.52531 terminal cancer patient 0.535978 All Free Clear 0.515267 Dermatol Venereol 0.632286 farmacológica medicamento dosis 0.550466 Clinical aspects 0.477546 Medicamento Dosis Comentarios 0.541353 Acta Derm Venereol 0.979711 Eisen AZ 0.543793 New York 0.832579 patients receiving 0.483634 Yosipovitch G 0.516371 mg diarios comenzar 0.507465 Abel EA 0.553787 Enterostomal Ther 0.474722 sistema nervioso central 0.522009 pruritus relief with 0.489446 policitemia vera 0.673444 Dermatol Ther 0.602936 Fitzpatrick TB 0.546636 Federman DD 0.567864 Bernhard JD 0.556935 chronic pruritus 0.522206	CLICK HERE
1884	National Cancer Institute	Html	es	Tratamiento de las neoplasias de células plasmáticas (incluso mieloma múltiple) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias de células plasmáticas (incluso mieloma múltiple).	mieloma múltiple grupo 0.317462 multicentre randomized study 0.314956 Rajkumar SV 0.360993 Durie BG 0.317277 Dispenzieri A 0.381536 primary plasma cell 0.32094 Lacy MQ 0.31455 extramedullary plasmacytoma 0.321972 light chain 0.421207 Myeloma Study Group 0.325182 versus deferred treatment 0.314362 plasma cell 0.333759 monoclonal gammopathies 0.324288 Radiat Oncol Biol 0.320101 multiple myeloma 0.968571 systemic amyloidosis 0.315374 stem cell transplantation 0.348134 International Myeloma Working 0.450729 células plasmáticas tipo 0.324338 proteína m 0.360491 Rosiñol L 0.316442 patients with 0.434191 patients with primary 0.318338 plasma cell leukemia 0.319942 UK Myeloma Forum 0.317407	células madre 0.338769 Myeloma Working Group 0.450073 International Blood 0.317358 primary systemic amyloidosis 0.314303 peripheral blood stem 0.321195 células plasmáticas oligosecretoras 0.325603 Therneau TM 0.332031 monoclonal gammopathy 0.501114 Dimopoulos MA 0.326344 Kumar SK 0.315489 lesiones óseas 0.347582 light chain amyloidosis 0.337292 International Staging System 0.324252 monoclonal sérica tipo 0.317411 Kyle RA 0.395277 Clin Oncol 0.474276 myeloma with 0.317498 Oncol Biol Phys 0.320425 mieloma múltiple estadio 0.31799 Nordic Myeloma Study 0.324636 with newly diagnosed 0.31487 células plasmáticas neoplasia 0.324857 mieloma múltiple igg 0.323238 patients with newly 0.318559	CLICK HERE
1912	National Cancer Institute	Html	es	Tratamiento de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles.	síndromes mielodisplásicos.Quimioterapia 0.302945 linfocítica aguda 0.307126 siguientes procedimientos 0.33161 siguientes aspectos 0.303162 Neurofibromatosis tipo 0.303799 células madre formadoras 0.308269 siguientes especialistas 0.302945 hueso compacto 0.308024 neoplasias mieloides 0.310246 célula madre mieloide 0.324347 Bultos indoloros 0.302618 líquido cefalorraquídeo 0.326401 leucemia mielomonocítica 0.41887 Instituto Nacional 0.305639 célula madre linfoide 0.318549 siguientes problemas 0.302781 leucemia mielógena 0.419565 neoplasias mielodisplásicas 0.302899 LMA recién 0.316713 cáncer regrese).El 0.307025 madre mieloides 0.328575 células madre mieloides 0.318746 leucemia promielocítica aguda 0.371662 células madre 0.977959 leucemia mielógena aguda 0.321693	leucemia aguda 0.310888 leucemia linfoblástica aguda 0.335277 síndromes mielodisplásicos 0.43219 enlace drugs approved 0.308769 Acute Myeloid Leukemia 0.309058 infantil recidivante 0.30755 Sudores nocturnos 0.302372 efectos tardíos 0.309904 médula ósea.Leucemia mielógena 0.31318 células cancerosas.El gemtuzumab 0.309349 punción espinal.Ampliar 0.30255 leucemia granulocítica aguda 0.320187 PDQ Tratamiento 0.305949 blastocitos mieloides 0.303489 tirosina cinasa 0.339619 sistema nervioso central 0.381371 leucemia mieloblástica aguda 0.320188 Physician Data Query 0.305829 enfermedades mieloides 0.315553 SMD)Algunos tratamientos 0.302284 revés.La prueba 0.301997 leucemia mieloide aguda 0.981978 célula madre 0.354129 siguientes sumarios 0.305018	CLICK HERE
1954	National Cancer Institute	Html	es	Tratamiento del mesotelioma maligno (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer del mesotelioma maligno.	siguientes procedimientos 0.614487 estadio iv 0.791187 Malignant Mesothelioma 0.549358 estadio ii 0.653957 estadios ia 0.559097 vía oral 0.54921 rayos x 0.916803 estadio ib 0.585037 enlace drugs approved 0.58335 estadio ia 0.583181 ondas sonoras 0.565775 líquido anormales.ampliar biopsia 0.679304 siguientes síntomas 0.602559 National Cancer Institute 0.545373 siguientes riesgos 0.53912	siguientes tratamientos 0.580411 quimioterapia intraperitoneal hipertérmica 0.640252 detalles minúsculos 0.572451 Instituto Nacional 0.580849 PDQ Tratamiento 0.591752 alta potencia 0.560897 presente sección 0.540992 partes distantes 0.551484 Physician Data Query 0.667975 siguientes sitios 0.687794 pequeña incisión 0.582002 ecografía ayuda 0.565218 cuerpo llamada ecograma 0.656058 siguientes pruebas 0.740981	CLICK HERE
2070	National Cancer Institute	Html	es	Inhibidores de la angiogénesis	Hoja informativa que describe el proceso de eliminación de suministro de sangre a los tumores. Incluye una lista de los cánceres en los que se está probando este enfoque.	vasos sanguíneos resultantes 0.32417 NCI de estudios 0.304711 llamadas metástasis 0.305878 posibles efectos 0.304824 Drug Administration 0.306756	células renales 0.307581 angiogénesis efectos 0.326284 Estados Unidos 0.315596 vasos sanguíneos 0.986577	CLICK HERE
2074	National Cancer Institute	Html	es	Lunares comunes, nevos displásicos y el riesgo de melanoma	Hoja informativa que trata de los lunares y de cómo algunos de ellos pueden relacionarse con el melanoma, el cual es el tipo más grave de cáncer de piel. La hoja informativa incluye fotos de las diferencias entre los lunares y el cáncer y habla de los factores de riesgo para el melanoma.	cutaneous melanoma 0.625563 American Medical Association 0.446245 American Academy 0.427461 Titus-Ernstoff L 0.428273 Farber MJ 0.430084 Retrieved July 0.486153 Cancer Statistics Review 0.452828 melanoma diagnosis 0.625391 raros casos 0.429111 SEER Web site 0.451878 Halpern A 0.427294 American Cancer Society 0.542367 Noone AM 0.428963 Holly EA 0.427203 Warycha MA 0.428668 National Cancer Institute 0.451063 Does Melanoma Look 0.709416 color café 0.453426 quemaduras solares 0.441604 estadounidenses —más 0.43587 atypical moles 0.48786 antecedentes familiares 0.432287 más anchos 0.493483	Family Physician 0.42998 página what does 0.683972 médicos familiares 0.43414 lámparas solares 0.871559 central risk factor 0.448185 patient with 0.429841 years beyond 0.429706 Rigel DS 0.428483 Estados Unidos 0.428522 Krapcho M 0.428389 PubMed Abstract 0.979256 Cyr PR 0.430249 única forma 0.527641 piel al sol 0.463391 Mole Look Like 0.64852 early melanoma detection 0.640669 página luz solar del nci 0.453944 Acta Dermato Venereologica 0.450034 Goodson AG 0.428558 Perry AE 0.427784 Cancer Journal 0.432434 Look Like 0.678163	CLICK HERE
16680	National Cancer Institute	Html	en	Cancer Moonshot℠ Implementation	Implementation teams are considering multiple ways to fund new programs as well as expansions of ongoing efforts to advance the goals of the Cancer Moonshot.	Cancer Moonshot-related research 0.688251 ongoing efforts 0.579887 funding opportunity announcements 0.69197 authorization 0.517804 oversight 0.515337 Cancer Moonshot portfolio 0.716496 academia 0.515431 Cancer Moonshot goals 0.684682 Century Cures Act 0.85793 expansions 0.51624 implementation teams 0.716347 email Partnerships_CancerMoonshot 0.582993 list 0.516345 Scientific Advisors 0.584259 important role 0.585193 longer-term scientific initiatives 0.700429 research opportunities 0.75591 multiple ways 0.591922 private sector 0.587499 Cancer Moonshot 0.987984 Cancer Moonshot initiatives 0.68956 concept proposals 0.656557 automatic email 0.583279 receipt 0.519207	NCI intramural staff 0.745934 cancer research community 0.682183 NCI extramural program 0.749793 Program Leadership Committee 0.655079 potential partners 0.586537 available FOAs 0.62206 NCI’s Board 0.674346 NIH institutes 0.582819 existing funds 0.59672 new research opportunities 0.683581 21st Century Cures 0.861565 scientific opportunities 0.594628 Blue Ribbon Panel 0.846596 BRP recommendation 0.740701 working groups 0.588634 new funding concepts 0.653803 BRP recommendations 0.654047 Public-private partnerships 0.590589 Cancer Moonshot implementation 0.678145 NCI advisory committees 0.753041 NCI’s Scientific 0.67691 report 0.517155 new programs 0.586358 funding mechanism 0.587953	CLICK HERE
16708	National Cancer Institute	Html	en	ALCHEMIST (The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): Questions and Answers	ALCHEMIST represents three integrated, precision medicine trials that are designed to identify people with early-stage lung cancer who have tumors that harbor certain uncommon genetic changes and evaluate whether drug treatments targeted against those mol	certain genetic alterations 0.511031 ALK gene rearrangement 0.86792 specific genetic alterations 0.510493 lung cancer 0.965003 ALK genetic alterations 0.561732 component trials 0.510228 National Clinical Trials 0.497396 clinical trials 0.62346 early-stage lung cancer 0.707269 EGFR gene mutation 0.628828 best treatment approach 0.483241 lung cancers 0.649896 ALK Treatment component 0.564764 ECOG-ACRIN Cancer Research 0.536673 ALK rearrangement 0.515701 non-small cell lung 0.519586 Adjuvant Lung Cancer 0.554841 EGFR gene mutations 0.510846 uncommon genetic changes 0.484048 ALCHEMIST treatment trial 0.613717 new treatment approaches 0.481108 lung carcinoid tumors 0.539366 early-stage lung cancers 0.57159 appropriate ALCHEMIST treatment 0.663904	ALK gene 0.888431 precision medicine trials 0.560161 tumor tissue 0.58358 United States 0.513049 Dana-Farber Cancer Institute 0.495276 ALK alterations 0.531283 small cell lung 0.519071 National Cancer Institute 0.484824 ALCHEMIST study 0.594796 cancer risk characteristics 0.487226 EGFR Treatment component 0.512344 participants 0.568322 ALCHEMIST treatment trials 0.868218 genetic alterations 0.637424 complete surgical removal 0.527484 Cancer Research Group 0.536403 early-stage lung adenocarcinoma 0.54246 cell lung cancer 0.575738 Cancer Genomics 0.482098 FDA-approved Vysis ALK 0.52631 ALCHEMIST screening trial 0.716569 ALCHEMIST trials 0.680442 standard therapy 0.505511 Clinical Trials Agreement 0.491455	CLICK HERE